NGF   Click here for help

GtoPdb Ligand ID: 5026

Synonyms: beta-nerve growth factor | beta-NGF | Oxervate® | Sentinel®
Approved drug
NGF is an approved drug (EMA (2017), FDA (2018))
Compound class: Endogenous peptide in human, mouse or rat
Comment: Recombinant NGF (cenegermin, also known as cenegermin-bkbj) is used clinically as a peripherally selective agonist of TrkA and LNGFR. Note that the recombinant peptide is two amino acids shorter than the endogenous peptide, with the carboxy-terminal RA (Arg-Ala) removed.
Species: Human
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Natural/Endogenous Targets
Target
nerve growth factor receptor
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
nerve growth factor receptor Ligand is endogenous in the given species Hs None - 6.0 pIC50 - 1
⤷ pIC50 6.0 (IC50 1x10-6 M) [1]
Additional information and targets (data relate to human unless otherwise stated)
Description Data Reference
Endogenous ligands at neurotrophic receptor tyrosine kinase 1 NGF (NGF, P01138) > neurotrophin-3 (NTF3, P20783)
Other ligands which bind to or alter the activity of this ligand
Key to terms and symbols Click column headers to sort
Ligand Sp. Type Action Value Parameter Concentration range (M) Reference
fasinumab Peptide Primary target of this compound Hs Antibody Binding 12.7 pKd - 2
⤷ pKd 12.7 (Kd 1.8x10-13 M) [2]
fulranumab Peptide Primary target of this compound Hs Antibody Binding 11.4 pKd - 4
⤷ pKd 11.4 (Kd 4x10-12 M) [4]
tanezumab Peptide Primary target of this compound Hs Antibody Binding 10.1 pKd - 3
⤷ pKd 10.1 (Kd 7x10-11 M) [3]
Description: Affinity of NGF of antibody E3 for human NGF.
Ligand mentioned in the following text fields
Tumour necrosis factor (TNF) receptor family comments
Type VII RTKs: Neurotrophin receptor/Trk family comments